Журнал "Медицинский совет" №2/2020

Для цитирования: Каратеев Д.Е., Лучихина Е.Л. Место таргетных синтетических препаратов в лечении ревматических заболеваний: фокус на тофацитиниб. Медицинский совет. 2020;(2):83–94. https://doi.org/10.21518/2079-701X-2020-2-83-94

Конфликт интересов: авторы заявляют об отсутствии конфликта интересов.

The role of targeted synthetic drugs in the treatment of rheumatic diseases: focus on tofacitinib

The treatment of immuno-inflammatory rheumatic diseases has advanced significantly in recent decades due to development of biological medications, which, however, are not without some weak points. They include immunogenicity, parenteral administration, and potentially insufficient stability of the composition of the drug. Great hopes are related to a relatively new class of targeted synthetic immunomodulatory drugs, currently represented in rheumatology by JAK kinase inhibitors (tofacitinib, baricitinib, upadacitinib) and phosphodiesterase 4 inhibitor (apremilast). The most actively developed group is JAK inhibitors that influence one of the most important signal pathway of immune system. This family includes 4 subtypes: JAK1, JAK2, JAK3 и tyrosine-kinase2 (TYK2). JAK-kinases selectively aggregate with cytoplasmic domains of different cytokine receptors, activation of which includes intracellular signal pathway JAK-STAT (Signal Transducer and Activator of Transcription). STAT proteins are responsible for transduction of the signals from more than 50 cytokines, hormones and growth factors that regulate key processes of survival, proliferation and differentiation of immune cells. The greatest practical experience achieved on tofacitinib. This medication approved in Russia for several indications: rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis. Clinical trials of III phase of ORAL series in rheumatoid arthritis and OPAL series in psoriatic arthritis showed high efficacy of Tofacitinib in different clinical situations. In Russian strategic trial REMARKA after treatment with Tofacitinib very fast improvement of the signs of activity was observed, 68,8% patients achieved low disease activity or remission at 6th month of follow-up. Russian open multi-center observational study of Tofacitinib in 101 patients with rheumatoid arthritis and insufficient efficacy of basic and biologic drugs showed achievement of low disease activity or remission in 60% patients, as well as significant improvement of quality of life with a very low frequency of withdrawals due to adverse events (less than 2%).

For citation: Karateev D.E., Luchikhina E.L. The role of targeted synthetic drugs in the treatment of rheumatic diseases: focus on tofacitinib. Meditsinskiy sovet = Medical Council. 2020;(2):83–94. (In Russ.) https://doi.org/10.21518/2079-701X-2020-2-83-94

Conflict of interest: the authors declare no conflict of interest.

Загрузить файл в формате PDF

Список литературы / References

1. Smolen J., Aletaha D., Bijlsma J.W.J., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637. https://doi.org/10.1136/ard.2009.123919.


2. Smolen J.S., Landewé R., Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. https://doi.org/10.1136/annrheumdis-2016-210715.


3. Burmester G.R., Bijlsma J.W.J., Cutolo M., McInnes I.B. Managing rheumatic and musculoskeletal diseases - past, present and future. Nat Rev Rheumatol. 2017;13(7):443-448. https://doi.org/10.1038/nrrheum.2017.95.


4. Насонов Е.Л., Мазуров В.И., Каратеев Д.Е., Лукина Г.В., Жиляев Е.В., Амирджанова В.Н., Муравьев Ю.В., Чичасова Н.В. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» - 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-494. Режим доступа: https://rheumatolog.su/media/media/2018/08/20/npr_1_2014.pdf.


5. Smolen J.S., Schöls M., Braun J. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3- 17. https://doi.org/10.1136/annrheumdis-2017-211734.
   


6. Каратеев Д.Е., Лучихина Е.Л., Мисиюк А.С. Российский и международный опыт применения ингибитора Янус-киназ при ревматоидном артрите. Медицинский совет. 2017;(10):87-92. https://doi.org/10.21518/2079-701X-2017-10-87-92.


7. Pincus T., Yazici Y., van Vollenhoven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some set-tings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006;33(12):2372-2375. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17143975.


8. Boers M. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: Case closed? Ann Intern Med. 2009;151(9):668-669. https://doi.org/10.1059/0003-4819-151-9-200911030-00013.
   


9. Каратеев Д.Е. Факторы, определяющие длительный успех терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Современная ревматология. 2015;9(3):54-60. https://doi.org/10.14412/1996-70122015-3-54-60.


10. Wolbink G.J., Aarden L.A., Dijkmans B.A. Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211-215. https://doi.org/10.1097/bor.0b013e328329ed8b.


11. Каратеев Д.Е. Вопросы иммуногенности биологических препаратов: теория и практика. Современная ревматология. 2009;3(1):67-72. Режим доступа: https://cyberleninka.ru/article/n/voprosy-immunogennosti-biologicheskih-preparatov-teoriya-i-praktika.


12. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011;13:112. https://doi.org/10.1186/ar3310.
    


13. Castañeda-Hernández G., Szekanecz Z., Mysler E., Azevedo V.F., Guzman R., Gutierrez M., Rodríguez W., Karateev D. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine. 2014;81(6):471-477. https://doi.org/10.1016/j.jbspin.2014.03.019.


14. Насонов Е.Л. Биоаналоги в ревматологии. Научно-практическая ревматология. 2016;54(6):628-640. https://doi.org/10.14412/19954484-2016-628-640.


15. Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O’Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843- 862. https://doi.org/10.1038/nrd.2017.201.


16. Kotyla P.J. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients? Biomed Res Int. 2018;2018:7492904. https://doi.org/10.1155/2018/7492904.


17. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29-33. https://doi.org/10.1016/j. cbpa.2016.03.006.


18. Ghoreschi K., Laurence A., O’Shea J. Janus kinases in immune cell signaling. Immunological Reviews. 2009;228(1):273-287. https://doi.org/10.1111/j.1600-065X.2008.00754.x.
    


19. Darnell J.R., Jr. STATS and gene regulation. Science. 1997;277(5332):1630-1635. https://doi.org/10.1126/science.277.5332.1630.


20. Malemud C.J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(5-6):117-127 https://doi.org/10.1177/1759720X18776224.


21. O’Shea J.J., Holland S.M., Staudt L.M. JAKs and STATs in Immunity, Immunodeficiency, and Cancer. The New England journal of medicine. 2013;368(2):161-170. https://doi.org/10.1056/NEJMra1202117.


22. Насонов Е.Л., Denisov L.N., Stanislav M.I. Новые аспекты фармакотерапии ревматоидного артрита: ингибиторы малых молекул. Научно¬практическая ревматология. 2012;50(2):66-75. https://doi.org/10.14412/1995-44842012-1276.


23. Каратеев Д.Е. Новое направление в патогенетической терапии ревматоидного артрита: первый ингибитор Янус-киназ тофацитиниб. Современная ревматология. 2014;8(1):39-44. https://doi.org/10.14412/1996-7012-2014-1-39-44.


24. Fleischmann R., Kremer J., Cush J., PlaceboControlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med. 2012; 367:495-507. https://doi.org/10.1056/NEJMoa1109071.


25. Meyer S.C., Levine R.L. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014;20(8):2051-2059. https://doi.org/10.1158/10780432.CCR-13-0279.


26. McLornan D.P., Khan A.A., Harrison C.N. Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep. 2015;10(4):370-379. https://doi.org/10.1007/s11899015-0284-z.


27. Schwartz D.M., Bonelli M., Gadina M., et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25-36. https://doi.org/10.1038/nrrheum.2015.167.


28. Kontzias A., Kotlyar A., Laurence A., et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseases. Curr Opin Pharmacol. 2012;12(4):464-470. https://doi.org/10.1016/j. coph.2012.06.008.


29. Morelli M., Scarponi C., Mercurio L. et al. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. J Immunol Res. 2018;2018:7897263. https://doi.org/10.1155/2018/7897263.
    


30. Goropevšek A., Holcar M., Avčin T. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus. Clin Rev Allergy Immunol. 2017;52(2):164-181. https://doi.org/10.1007/s12016-016-8550-y.


31. Damsky W., King B.A. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-744. https://doi.org/10.1016/j.jaad.2016.12.005.


32. Pallandre J.R., Brillard E., Créhange G. et al. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol. 2007;179(11):7593- 7604. https://doi.org/10.4049/jimmunol.179.11.7593.


33. Avalle L., Camporeale A., Camperi A., Poli V. STAT3 in cancer: A double edged sword. Cytokine. 2017;98:42-50. https://doi.org/10.1016/j. cyto.2017.03.018.


34. Srivastava J., DiGiovanni J. Non-canonical Stat3 signaling in cancer. Mol Carcinog. 2016;55(12):1889-1898. https://doi.org/10.1002/mc.22438.
    


35. Fleischmann R., Kremer J., Cush J. et al; for the ORAL Solo Investigators. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med. 2012;367:495-507. https://doi.org/10.1056/NEJMoa1109071.


36. Lee E.B., Fleischmann R., Hall S., Wilkinson B., Bradley J.D., et al; ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377-2386. https://doi.org/10.1056/NEJMoa1310476.


37. Burmester G.R., Blanco R., Charles-Schoeman C., Wollenhaupt J., et al; ORAL Step investigators.. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-460. https://doi.org/10.1016/S0140-6736(12)61424-X.


38. van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., Meijide J.A.G., Wagner S., et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. NEJM. 2012;367(6):508- 519. https://doi.org/10.1056/NEJMoa1112072.


39. van der Heijde D., Tanaka Y., Fleischmann R. et al; ORAL Scan Investigators. Tofacitinib (CP690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559- 570. https://doi.org/10.1002/art.37816.


40. Fleischmann R., Mease P.J., Schwartzman S., Hwang L.-J., Soma K., Connell C.A., Takiya L., Bananis E. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol. 2017;36(1):15-24. https://doi.org/10.1007/s10067-016-3436-1.


41. Kremer J., Zhan-Guo Li, Hall S., et al. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2013;159(4):253-261. https://doi.org/10.7326/00034819-159-4-201308200-00006.


42. Strand V., Ahadieh S., French J. Systematic review and meta-analysis of serious infections with tofacitinib and biologic diseasemodifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. https://doi.org/10.1186/s13075015-0880-2.


43. Каратеев Д.Е. Ингибиторы киназ при ревматоидном артрите: реальность и перспективы. Медицинский Совет. 2013;(12):90-96. https://doi.org/10.21518/2079-701X-2013-12-90-96.


44. Каратеев Д.Е., Лучихина Е.Л., Муравьев Ю.В., Демидова Н.В., Grineva G.I., Новикова Д.С., Александрова Е.Н., Новиков А.А., Смирнов А.В., Волков А.В., Avdeyeva A.S., Lopareva E.V., Олюнин Ю.А., Лукина Г.В., Попкова Т.В., Насонов Е.Л. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117- 125. https://doi.org/10.14412/1995-4484-2013-637.


45. Насонов Е.Л., Каратеев Д.Е., Сатыбалдыев А.М., Лучихина Е.Л., Лукина Г.В., Николенко М.В., и соавт. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2015;53(5):472- 484. https://doi.org/10.14412/1995-4484-2015-472-484.


46. Лучихина Е.Л., Каратеев Д.Е., Демидова Н.В., Мисиюк А.С., Александрова Е.Н., Новиков А.А., Смирнов А.В., Насонов Е.Л. Эффективность и безопасность терапии тофацитинибом у больных активным ревматоидным артритом с резистентностью к стандартной терапии: предварительные результаты открытого клинического исследования. Современная ревматология. 2016;10(2):17-23. https://doi.org/10.14412/1996-7012-2016-2-17-23.


47. Каратеев Д.Е., Абдулганиева Д.И., Бабаева А.Р., Баранов А.А., Евстигнеева Л.П., Иванова О.Н., Лукина Г.В., Лучихина Е.Л., Мазуров В.И., Мисиюк А.С., Семагина О.В., Сизиков А.Э., Сороцкая В.Н. Применение тофацитиниба для лечения больных ревматоидным артритом, резистентных к синтетическим и биологическим базисным противовоспалительным препаратам, в реальной клинической практике (результаты многоцентрового наблюдательного исследования). Современная ревматология. 2016;10(3):52-61. https://doi.org/10.14412/1996-7012-2016-3-52-61.


48. Каратеев Д.Е., Абдулганиева Д.И., Бабаева А.Р., Баранов А.А., Евстигнеева Л.П., Иванова О.Н., Лукина Г.В., Лучихина Е.Л., Мазуров В.И., Мисиюк А.С., Семагина О.В., Сизиков А.Э., Сороцкая В.Н. Влияние тофацитиниба на показатели функции и качества жизни у больных ревматоидным артритом, резистентных к синтетическим и биологическим базисным противовоспалительным препаратам, в реальной клинической практике (результаты многоцентрового наблюдательного исследования). Современная ревматология. 2017;11(1):12-18. https://doi.org/10.14412/19967012-2017-1-12-18.


49. Luchikhina L., Karateev D., Borisova M., Loukina G., Demidova N., Nasonov E. Comparative efficacy of tofacitinib and biologic DMARDS in patients with rheumatoid arthritis with insufficient response to subcutaneous methotrexate in clinical practice. Ann Rheum Dis. 2018;77(Suppl 2):A1403. https://doi.org/10.1136/annrheumdis-2018-eular.7306.


50. Coates L.C., Kavanaugh A., Mease P.J., Soriano E.R., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-1071. https://doi.org/10.1002/art.39573.


51. Kuo C.M., Tung T.H., Wang S.H., Chi C.C. Efficacy and safety of tofacitinib for moderate-tosevere plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32(3):355-362. https://doi.org/10.1111/jdv.14695.


52. Fleming P. Tofacitinib: a new oral Janus kinase inhibitor for psoriasis. Br J Dermatol. 2019;180(1):13-14. https://doi.org/10.1111/bjd.17323.


53. Wang T.S., Tsai T.F. Tofacitinib in psoriatic arthritis. Immunotherapy. 2017;9(14):1153- 1163. https://doi.org/10.2217/imt-2017-0087.


54. Paik J., Deeks E.D. Tofacitinib: A Review in Psoriatic Arthritis. Drugs. 2019;79(6):655-663. https://doi.org/10.1007/s40265-019-01091-3.


55. Mease P., Hall S., Fitzgerald O., van der Heijde D., Merola J.F., Avila-Zapata F., et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537-1550. https://doi.org/10.1056/NEJMoa1615975.


56. Gladman D., Rigby W., Azevedo V.F., Behrens F., Blanco R., Kaszuba A., et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525- 1536. https://doi.org/10.1056/NEJMoa1615977.


57. Strand V., de Vlam K., Covarrubias-Cobos J.A., Mease P.J. et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806. https://doi.org/10.1136/rmdopen-2018-000806.


58. Strand V., de Vlam K., Covarrubias-Cobos J.A., Mease P.J. et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019;5(1):e000808. https://doi.org/10.1136/rmdopen-2018-000808.


59. Nash P., Coates L.C., Fleischmann R., Papp K.A. et al. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018;5(2):567-582. https://doi.org/10.1007/s40744-018-0131-5.


60. Helliwell P., Coates L.C., FitzGerald O., Nash P. et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242. https://doi.org/10.1186/s13075-0181739-0.


61. Nash P., Coates L.C., Kivitz A.J., Mease P.J., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). Available at: https://acrabstracts.org/abstract/safety-and-efficacy-oftofacitinib-an-oral-janus-kinase-inhibitor-upto-36-months-in-patients-with-active-psoriatic-arthritis-data-from-the-third-interim-analysis-of-opal-balance-an-open-label-lo.


62. Nash P., Coates L., Kivitz A., et al. SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2018;77:1010-1011. https://doi.org/10.1136/annrheumdis-2018-eular.3115.
    


63. Насонов Е.Л., Лила А.М. Ингибиторы Янускиназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. https://doi.org/10.14412/1995-4484-2019-8-16.


64. Virtanen A.T., Haikarainen T., Raivola J., Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. https://doi.org/10.1007/s40259-019-00333-w.